The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 15, issue 9, 2014

Analysing coverage decision-making: opening Pandora’s box? pp. 899-906

Katharina Fischer and Reiner Leidl

Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data pp. 907-916

Elisabeth Brock, Peter Braunhofer, Josef Troxler and Heinz Schneider

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain pp. 917-925

Álvaro Hidalgo-Vega, Juan Ramos-Goñi and Renata Villoro

Patient hospital choice for hip replacement: empirical evidence from the Netherlands pp. 927-936

Puck Beukers, Ron Kemp and Marco Varkevisser

Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs pp. 937-951

Kurt Brekke, Dag Dalen and Tor Holmås

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I) pp. 953-966

Uwe Zettl, Thomas Henze, Ute Essner and Peter Flachenecker

Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD pp. 967-977

Clazien Bouwmans, Annemarie Kolk, Mark Oppe, Saskia Schawo, Elly Stolk, Michel Agthoven, Jan Buitelaar and LeonaHakkaart Roijen

The impact of ageing on health care expenditures: a study of steepening pp. 979-989

Fredrik Gregersen

Brand switching or reduced consumption? A study of how cigarette taxes affect tobacco consumption pp. 991-998

Chiang-Ming Chen, Kuo-Liang Chang, Lin Lin and Jwo-Leun Lee

Cost effects of hospital mergers in Portugal pp. 999-1010

Helda Azevedo and Ceu Mateus

Volume 15, issue 8, 2014

Considering productivity loss in cost-effectiveness analysis: a new approach pp. 787-790

Afschin Gandjour

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France pp. 791-800

Jacques Touchon, Jean Lachaine, Catherine Beauchemin, Anna Granghaud, Benoit Rive and Sébastien Bineau

The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening pp. 801-812

Pauline Chauvin, Jean-Michel Josselin and Denis Heresbach

How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011 pp. 813-828

Astrid Kiil and Kurt Houlberg

Methodological reviews of economic evaluations in health care: what do they target? pp. 829-840

Maria-Florencia Hutter, Roberto Rodríguez-Ibeas and Fernando Antonanzas

On social polarization and ordinal variables: the case of self-assessed health pp. 841-851

Alessio Fusco and Jacques Silber

The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study pp. 853-867

Petra Baji, Milena Pavlova, László Gulácsi, Miklos Farkas and Wim Groot

Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model pp. 869-883

G. Ramos, Antoinette Asselt, Sandra Kuiper, Johan Severens, Tanja Maas, Edward Dompeling, J. Knottnerus and Onno Schayck

Population ageing and healthcare expenditure projections: new evidence from a time to death approach pp. 885-896

Claudia Geue, Andrew Briggs, James Lewsey and Paula Lorgelly

Erratum to: Cost-effectiveness of febuxostat in chronic gout pp. 897-897

Stephen Beard, Birgitta Scheele, George Nuki and Isobel Pearson

Volume 15, issue 7, 2014

HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain pp. 675-680

László Gulácsi and Márta Péntek

Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making pp. 681-695

Karin Cerri, Martin Knapp and Jose Luis Fernandez

Lead me not into temptation: drug price regulation and dispensing physicians in Switzerland pp. 697-708

Maurus Rischatsch

A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions pp. 709-716

Douwe Postmus, Tommi Tervonen, Gert Valkenhoef, Hans Hillege and Erik Buskens

Persistence of physical activity in middle age: a nonlinear dynamic panel approach pp. 717-735

Narimasa Kumagai and Seiritsu Ogura

Choice of insurer for basic health insurance restricted by supplementary insurance pp. 737-746

Daniëlle Duijmelinck and Wynand Ven

Employment effects of hospital privatization in Germany pp. 747-757

Mareike Heimeshoff, Jonas Schreyögg and Oliver Tiemann

Health tourism on the rise? Evidence from the Balance of Payments Statistics pp. 759-766

Chung-Ping Loh

Cost-effectiveness of lung transplantation and its evolution: the Portuguese case pp. 767-772

Luis Mendonça, Julian Perelman, Vanessa Rodrigues and José Fragata

Applying discrete choice modelling in a priority setting: an investigation of public preferences for primary care models pp. 773-785

Chiara Seghieri, Alessandro Mengoni and Sabina Nuti

Volume 15, issue 6, 2014

Health-related development aid: what comes after it? pp. 563-566

Steffen Fleßa

The effect of job loss on body weight during an economic collapse pp. 567-576

Sif Jónsdóttir and Tinna Ásgeirsdóttir

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation pp. 577-589

Jörg Ruof, Friedrich Schwartz, J.-Matthias Schulenburg and Charalabos-Markos Dintsios

Does health promote economic growth? Portuguese case study: from dictatorship to full democracy pp. 591-598

Sónia Morgado

Association between fee-for-service expenditures and morbidity burden in primary care pp. 599-610

Troels Kristensen, Kim Olsen, Henrik Schroll, Janus Thomsen and Anders Halling

Preference for practice: a Danish study on young doctors’ choice of general practice using a discrete choice experiment pp. 611-621

Line Pedersen and Dorte Gyrd-Hansen

An empirical analysis of the multimarket contact theory in pharmaceutical markets pp. 623-643

Javier Coronado, Sergi Jimenez-Martin and Pedro Marín

Can health public expenditure reduce the tragic consequences of road traffic accidents? The EU-27 experience pp. 645-652

José Castillo-Manzano, Mercedes Castro-Nuño and Xavier Fageda

Costs of diabetes and its complications in Poland pp. 653-660

Joanna Leśniowska, Agata Schubert, Michał Wojna, Iwona Skrzekowska-Baran and Marta Fedyna

Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France pp. 661-673

Hassan Serrier, Hélène Sultan-Taieb, Danièle Luce and Sophie Béjean

Volume 15, issue 5, 2014

Health technology assessments in England: an analysis of the NICE Medical Technologies Evaluation Programme pp. 449-452

William Green and John Hutton

Cost-effectiveness of febuxostat in chronic gout pp. 453-463

Stephen Beard, Birgitta Scheele, George Nuki and Isobel Pearson

Predicting productivity based on EQ-5D: an explorative study pp. 465-475

Marieke Krol, Elly Stolk and Werner Brouwer

The effects of rebate contracts on the health care system pp. 477-487

Julia Graf

Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores pp. 489-496

Fang-Ju Lin, Jennifer Samp, Alexis Munoz, Pei Wong and A. Pickard

Explaining variations in breast cancer screening across European countries pp. 497-514

Ansgar Wübker

Identifying covariates of population health using extreme bound analysis pp. 515-531

Fabrizio Carmignani, Sriram Shankar, Eng Joo Tan and Kam Ki Tang

Testing the red herring hypothesis on an aggregated level: ageing, time-to-death and care costs for older people in Sweden pp. 533-551

Martin Karlsson and Florian Klohn

Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach pp. 553-561

Arieh Gavious, Dan Greenberg, Ariel Hammerman and Ella Segev

Volume 15, issue 4, 2014

Orphan drugs policies: a suitable case for treatment pp. 335-340

Michael Drummond and Adrian Towse

Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based Cohort study and Markov model pp. 341-351

Martin Gulliford, Judith Charlton, Nawaraj Bhattarai, Christopher Charlton and Caroline Rudisill

Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain pp. 353-362

Carole Dembek, Leigh White, Jayson Quach, Andrea Szkurhan, Nazia Rashid and M. Blasco

Optimal choice on prevention and cure: a new economic analysis pp. 363-372

Mario Menegatti

Announcement effects of health policy reforms: evidence from the abolition of Austria’s baby bonus pp. 373-388

Beatrice Brunner and Andreas Kuhn

Valuing health at the end of life: an empirical study of public preferences pp. 389-399

Koonal Shah, Aki Tsuchiya and Allan Wailoo

Explaining differences in remuneration rates of nursing homes in Germany pp. 401-410

Roman Mennicken, Boris Augurzky, Heinz Rothgang and Juergen Wasem

Effects of health care decentralization in Spain from a citizens’ perspective pp. 411-431

José Ignacio Antón, Rafael Muñoz de Bustillo, Enrique Fernandez-Macias and Jesús Rivera

Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries pp. 433-437

Manuel Hens, Ana Villaverde-Hueso, Veronica Alonso, Ignacio Abaitua and Manuel Posada de la Paz

Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD pp. 439-445

Rodrigo Camejo, Clare McGrath, Marisa Miraldo and Frans Rutten

Erratum to: Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD pp. 447-447

Rodrigo Refoios Camejo, Clare McGrath, Marisa Miraldo and Frans Rutten

Volume 15, issue 3, 2014

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? pp. 223-228

María-Isabel Farfan-Portet, Sophie Gerkens, Isabelle Lepage-Nefkens, Irmgard Vinck and Frank Hulstaert

Low birth weight and health expenditures from birth to late adolescence pp. 229-242

Michael Hummer, Thomas Lehner and Gerald Pruckner

Economic evaluation of nurse-led intensive care follow-up programmes compared with standard care: the PRaCTICaL trial pp. 243-252

R. Hernández, D. Jenkinson, L. Vale and B. Cuthbertson

Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity pp. 253-263

Bruce Wang, Edwin Wong, Rafael Alfonso-Cristancho, Hao He, David Flum, David Arterburn, Louis Garrison and Sean Sullivan

Education, cognition, health knowledge, and health behavior pp. 265-279

Naci Mocan and Duha Altindag

Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling? pp. 281-288

Feng Xie, Eleanor Pullenayegum, Kathryn Gaebel, Mark Oppe and Paul Krabbe

The effect of quality and socio-demographic variables on efficiency measures in primary health care pp. 289-302

José Cordero Ferrera, Eva Cebada and Luis Murillo Zamorano

Health, social and economic consequences of hypersomnia: a controlled national study from a national registry evaluating the societal effect on patients and their partners pp. 303-311

Poul Jennum, Rikke Ibsen, Kirsten Avlund and Jakob Kjellberg

Blood donation as a public good: an empirical investigation of the free rider problem pp. 313-321

Ignacio Abasolo and Aki Tsuchiya

Equity in specialist waiting times by socioeconomic groups: evidence from Spain pp. 323-334

Ignacio Abasolo, Miguel Negrín-Hernández and Jaime Pinilla

Volume 15, issue 2, 2014

Is the US “leading from behind” on health policy? pp. 113-116

Peter Neumann and Cayla Saret

Is there room for containing healthcare costs? An analysis of regional spending differentials in Italy pp. 117-132

Maura Francese and Marzia Romanelli

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data pp. 133-142

Simon Frey, Roland Linder, Georg Juckel and Tom Stargardt

Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism pp. 143-156

Moshe Levy and Adi Rizansky

Economic evaluations of homeopathy: a review pp. 157-174

Petter Viksveen, Zofia Dymitr and Steven Simoens

Hospital efficiency under prospective reimbursement schemes: an empirical assessment for the case of Germany pp. 175-186

Helmut Herwartz and Christoph Strumann

The impact of health worker migration on development dynamics: evidence of wealth effects from Africa pp. 187-201

Simplice Asongu

Socioeconomic inequalities in adult obesity risk in Canada: trends and decomposition analyses pp. 203-221

Mohammad Hajizadeh, M. Karen Campbell and Sisira Sarma

Volume 15, issue 1, 2014

The organ crisis: a disaster of our own making pp. 1-5

Thomas Beard and Rigmar Osterkamp

Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries pp. 1-4

László Gulácsi

Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries pp. 1-4

László Gulácsi

Statistical and regulatory considerations in assessments of interchangeability of biological drug products pp. 5-11

Lászlo Tóthfalusi, László Endrényi and Shein-Chung Chow

Statistical and regulatory considerations in assessments of interchangeability of biological drug products pp. 5-11

Lászlo Tóthfalusi, László Endrényi and Shein-Chung Chow

Health state utilities for skeletal-related events secondary to bone metastases pp. 7-18

Louis Matza, Karen Chung, Kate Brunt, John Brazier, Ada Braun, Brooke Currie, Andrew Palsgrove, Evan Davies and Jean-Jacques Body

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria pp. 13-25

László Gulácsi, Alexandru M. Rotar, Maciej Niewada, Olga Löblová, Fanni Rencz, Guenka Petrova, Imre Boncz and Niek S. Klazinga

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria pp. 13-25

László Gulácsi, Alexandru Rotar, Maciej Niewada, Olga Löblová, Fanni Rencz, Guenka Petrova, Imre Boncz and Niek Klazinga

The impact of tobacco prices on smoking onset in Vietnam: duration analyses of retrospective data pp. 19-39

G Emmanuel Guindon

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries pp. 27-34

László Gulácsi, Fanni Rencz, Márta Péntek, Valentin Brodszky, Ruth Lopert, Noémi V. Hevér and Petra Baji

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries pp. 27-34

László Gulácsi, Fanni Rencz, Márta Péntek, Valentin Brodszky, Ruth Lopert, Noémi Hevér and Petra Baji

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries pp. 35-43

Márta Péntek, Gyula Poór, Piotr Wiland, Martina Olejárová, Marek Brzosko, Catalin Codreanu, Nóra Brodszky and László Gulácsi

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries pp. 35-43

Márta Péntek, Gyula Poór, Piotr Wiland, Martina Olejárová, Marek Brzosko, Catalin Codreanu, Valentin Brodszky and László Gulácsi

Willingness-to-accept reductions in HIV risks: conditional economic incentives in Mexico pp. 41-55

Omar Galarraga, Sandra Sosa-Rubí, César Infante, Paul Gertler and Stefano Bertozzi

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis pp. 45-52

Petra Baji, Márta Péntek, Sándor Szántó, Pál Géher, László Gulácsi, Orsolya Balogh and Valentin Brodszky

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis pp. 45-52

Petra Baji, Márta Péntek, Sándor Szántó, Pál Géher, László Gulácsi, Orsolya Balogh and Valentin Brodszky

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison pp. 53-64

Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi and Valentin Brodszky

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison pp. 53-64

Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi and Valentin Brodszky

The effect of health on labour supply in nine former Soviet Union countries pp. 57-68

Yevgeniy Goryakin, Lorenzo Rocco, Marc Suhrcke, Bayard Roberts and Martin McKee

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries pp. 65-71

Valentin Brodszky, Petra Baji, Orsolya Balogh and Márta Péntek

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries pp. 65-71

Valentin Brodszky, Petra Baji, Orsolya Balogh and Márta Péntek

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom pp. 69-82

Yevgeniy Samyshkin, Robert Kotchie, Ann-Christin Mörk, Andrew Briggs and Eric Bateman

Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective pp. 73-82

Márta Péntek, Bernadette Rojkovich, László Czirják, Pál Géher, Péter Keszthelyi, Attila Kovács, László Kovács, Zita Szabó, Zoltán Szekanecz, László Tamási, Ágnes Edit Tóth, Ilona Ujfalussy, Noémi Vártokné Hevér, Bálint Strbák, Petra Baji, Valentin Brodszky and László Gulácsi

Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective pp. 73-82

Márta Péntek, Bernadette Rojkovich, László Czirják, Pál Géher, Péter Keszthelyi, Attila Kovács, László Kovács, Zita Szabó, Zoltán Szekanecz, László Tamási, Ágnes Tóth, Ilona Ujfalussy, Noémi Hevér, Bálint Strbák, Petra Baji, Valentin Brodszky and László Gulácsi

Changes in the remuneration system for general practitioners: effects on contact type and consultation length pp. 83-91

Christel Dijk, Robert Verheij, Hans te Brake, Peter Spreeuwenberg, Peter Groenewegen and Dinny Bakker

Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists pp. 83-92

Márta Péntek, László Gulácsi, Bernadette Rojkovich, Valentin Brodszky, Job Exel and Werner Brouwer

Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists pp. 83-92

Márta Péntek, László Gulácsi, Bernadette Rojkovich, Valentin Brodszky, Job van Exel and Werner Brouwer

Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique pp. 93-112

Bonny Parkinson, Sallie-Anne Pearson and Rosalie Viney

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis pp. 93-100

Katalin Gulyas, Nora Bodnar, Zsofia Nagy, Szilvia Szamosi, Agnes Horvath, Andrea Vancsa, Edit Vegh, Zoltan Szabo, Gabriella Szucs, Zoltan Szekanecz and Sandor Szanto

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis pp. 93-100

Katalin Gulyas, Nora Bodnar, Zsofia Nagy, Szilvia Szamosi, Agnes Horvath, Andrea Vancsa, Edit Vegh, Zoltan Szabo, Gabriella Szucs, Zoltan Szekanecz and Sandor Szanto

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres pp. 101-109

Orsolya Balogh, Valentin Brodszky, László Gulácsi, Emese Herédi, Krisztina Herszényi, Hajnalka Jókai, Sarolta Kárpáti, Petra Baji, Éva Remenyik, Andrea Szegedi and Péter Holló

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres pp. 101-109

Orsolya Balogh, Valentin Brodszky, László Gulácsi, Emese Herédi, Krisztina Herszényi, Hajnalka Jókai, Sarolta Kárpáti, Petra Baji, Éva Remenyik, Andrea Szegedi and Péter Holló

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary pp. 111-119

Emese Herédi, Fanni Rencz, Orsolya Balogh, László Gulácsi, Krisztina Herszényi, Péter Holló, Hajnalka Jókai, Sarolta Kárpáti, Márta Péntek, Éva Remenyik, Andrea Szegedi and Valentin Brodszky

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary pp. 111-119

Emese Herédi, Fanni Rencz, Orsolya Balogh, László Gulácsi, Krisztina Herszényi, Péter Holló, Hajnalka Jókai, Sarolta Kárpáti, Márta Péntek, Éva Remenyik, Andrea Szegedi and Valentin Brodszky

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics pp. 121-128

Mandel D. Michael, Anita Bálint, Barbara D. Lovász, László Gulácsi, Bálint Strbák, Petra A. Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka K. Szilágyi, Anna Mohás, Tamás Molnár and Péter L. Lakatos

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics pp. 121-128

Mandel Michael, Anita Bálint, Barbara Lovász, László Gulácsi, Bálint Strbák, Petra Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka Szilágyi, Anna Mohás, Tamás Molnár and Péter Lakatos

Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics pp. 129-129

Michael D. Mandel, Anita Bálint, Barbara D. Lovász, László Gulácsi, Bálint Strbák, Petra A. Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka K. Szilágyi, Anna Mohás, Tamás Molnár and Péter L. Lakatos

Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics pp. 129-129

Michael Mandel, Anita Bálint, Barbara Lovász, László Gulácsi, Bálint Strbák, Petra Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka Szilágyi, Anna Mohás, Tamás Molnár and Péter Lakatos

Economic burden of long-term care of rheumatoid arthritis patients in Hungary pp. 131-135

Zoltán Horváth, Andor Sebestyén, August Österle, Dóra Endrei, József Betlehem, András Oláh, László Imre, Gabriella Bagosi and Imre Boncz

Economic burden of long-term care of rheumatoid arthritis patients in Hungary pp. 131-135

Zoltán Horváth, Andor Sebestyén, August Österle, Dóra Endrei, József Betlehem, András Oláh, László Imre, Gabriella Bagosi and Imre Boncz

Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010 pp. 137-141

Imre Boncz, Réka Vajda, István Ágoston, Dóra Endrei and Andor Sebestyén

Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010 pp. 137-141

Imre Boncz, Réka Vajda, István Ágoston, Dóra Endrei and Andor Sebestyén